GQ-177

GQ-177 is a novel thiazolidinedione-class small molecule that acts as a partial and selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist[1]. It improves obesity-associated metabolic dysfunction, including insulin resistance and dyslipidemia, and demonstrates atheroprotective effects in preclinical mouse models of diet-induced obesity and atherosclerosis[1]. Unlike full PPARγ agonists, GQ-177 enhances plasma adiponectin and GLUT4 expression in adipose tissue without increasing body weight or fat accumulation, and it upregulates hepatic proteins involved in lipid metabolism[1]. The drug is developed for the treatment of metabolic diseases such as obesity, diabetes, and atherosclerosis[1][10].